Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV nucleoside reverse transcriptase inhibitor, in Treatment-Experienced HIV-1-Infected Subjects

Trial Profile

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV nucleoside reverse transcriptase inhibitor, in Treatment-Experienced HIV-1-Infected Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Censavudine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top